BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/24/2021 7:26:32 AM | Browse: 359 | Download: 677
 |
Received |
|
2020-11-16 03:12 |
|
Peer-Review Started |
|
2020-11-08 09:58 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-12-21 20:12 |
|
Revised |
|
2021-01-01 10:44 |
|
Second Decision |
|
2021-05-20 13:17 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-05-20 13:57 |
|
Articles in Press |
|
2021-05-20 13:57 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-05-27 11:14 |
|
Publish the Manuscript Online |
|
2021-06-24 07:26 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Controversies’ clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
George D Liatsos |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
George D Liatsos, MD, PhD, Chief Doctor, Department of Internal Medicine , "Hippokration" General Hospital, 114 Vass. Sophia’s Ave, Athens 11527, Attiki, Greece. geoliatsos@yahoo.gr |
| Key Words |
Covid-19; Ribavirin; Severe acute respiratory syndrome-associated coronavirus; Middle east respiratory syndrome coronavirus; Measles; Treatment |
| Core Tip |
Documented by accumulated data from coronaviruses studies and considering six identified pitfalls to which most of the studies fall victim, the early antiviral treatment is crucial for reducing viral load, transmission, and preventing disease severity. In coronavirus disease 2019, initiation of interferon-β plus ribavirin plus lopinavir/ritonavir is beneficial when targeting selected patients early during Stage I, and is a regimen that can be administered while the patient is at home in quarantine. If disease progresses to Stages IIb-III, corticosteroids (mainly pulsed methylprednisolone) are effective, but if they fail or extrapulmonary systemic hyperinflammation syndrome develops, tocilizumab (or anakinra) should be co-administered. |
| Publish Date |
2021-06-24 07:26 |
| Citation |
Liatsos G. Controversies’ clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages. World J Clin Cases 2021; 9(19): 5135-5178 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i19/5135.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i19.5135 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
